ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials

Tang, Tao; Liu, Jie; Zuo, Keqiang; Cheng, Jie; Chen, Linyin; Lu, Chenhui; Han, Shilong; Xu, Jichong; Jia, Zhongzhi; Ye, Meng; Pei, Erli; Zhang, Xiaoping*; Li, Maoquan同济大学
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS2015-7DOI: 10.1177/1074248414565666
19被引1阅读
引用收藏
分享

摘要

Background: Coumarin anticoagulants (acenocoumarol, phenprocoumon, and warfarin) are generally used for the prevention of stroke in patients with atrial fibrillation or for the therapy and prevention of venous thromboembolism. However, the safe use of coumarin anticoagulants is restricted by a narrow therapeutic window and large interindividual dosing variations. Some studies found that the effectiveness and safety of coumarin anticoagulants therapy were increased by pharmacogenetic-guided dosing algorithms, while others found no significant effect of genotype-guided therapy. Methods: Four electronic databases were searched from January 1, 2000, to March 1, 2014, for randomized controlled trials of patients who received coumarin anticoagulants according to genotype-guided dosing algorithms. The primary outcome was the percentage of time that the international normalized ratio (INR) was within the normal range (2.0-3.0). Secondary outcomes included major bleeding events, thromboembolic events, and INR 4 events. Results: Eight studies satisfied the inclusion and exclusion criteria. Genotype-guided dosing of coumarin anticoagulants improved the percentage of time within the therapeutic INR range (95% confidence interval [CI], 0.02-0.28; P = .02; I-2 = 70%). Subgroup analysis was performed after dividing the nongenotype-guided group into a standard-dose group (95% CI, 0.14-0.49; P = .0004; I-2 = 50%) and a clinical variables-guided dosing algorithm group (95% CI, -0.07-0.15; P = .48; I-2 = 34%). There is a statistically significant reduction in numbers of secondary outcomes (INR 4 events, major bleeding events, and thromboembolic events; 95% CI, 0.79-1.00; P = .04). Subgroup analysis of secondary outcomes showed no significant difference between genotype-guided dosing and clinical variables-guided dosing (95% CI, 0.84-1.10; P = .57; I-2 = 11%), but genotype-guided dosing reduced secondary outcomes compared with standard dosing (95% CI, 0.62-0.92; P = .006; I-2 = 0%). Conclusions: This meta-analysis showed that genotype-guided dosing increased the effectiveness and safety of coumarin therapy compared with standard dosing but did not have advantages compared with clinical variables-guided dosing.

学科与关键词

关键词
genotype guidedanticoagulationcoumarinmeta-analysis
相关
加载中…
  • CYP2C9 and VKORC1 genotype-guided individualized warfarin therapy in Chinese patients with acute pulmonary thromboembolism: a randomized controlled clinical study
    Jin, Heng*; Jiang, Feng; Wei, Jun; Yao, Ying; Yuan, Hengjie; Yu, Muming; Qi, Anlong; Chai, YanfenInternational Journal of Clinical and Experimental Medicine, 2017, 10(3): 5595-5602.被引 11
  • Warfarin pharmacogenetics
    Johnson, Julie A.*; Cavallari, Larisa H.Trends in Cardiovascular Medicine, 2015, 25(1): 33-41.被引 115
  • Warfarin pharmacogenetics: A controlled dose-response study in healthy subjects
    Kadian-Dodov, Daniella L.*; van der Zee, Sarina A.; Scott, Stuart A.; Peter, Inga; Martis, Suparna; Doheny, Dana O.; Rothlauf, Elizabeth B.; Lubitz, Steven A.; Desnick, Robert J.; Halperin, Jonathan L.VASCULAR MEDICINE, 2013, 18(5): 290-297.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
发表日期
2015-07
卷期
第 20 卷, 第 4 期
页码
387-394
DOI
10.1177/1074248414565666
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q3
成果收录
SCIE

作者

  • T

    Tang, Tao (第一作者)

    tongji univ

  • L

    Liu, Jie

    tongji univ

查看全部 13 位作者收起作者
  • Z

    Zuo, Keqiang

    tongji univ

  • C

    Cheng, Jie

    tongji univ

  • C

    Chen, Linyin

  • L

    Lu, Chenhui

    tongji univ

  • H

    Han, Shilong

    tongji univ

  • X

    Xu, Jichong

    tongji univ

  • J

    Jia, Zhongzhi

    tongji univ

  • Y

    Ye, Meng

    tongji univ

  • P

    Pei, Erli

    tongji univ

  • Z

    Zhang, Xiaoping (通讯)

    tongji univ

  • L

    Li, Maoquan

    tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417